<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140606</url>
  </required_header>
  <id_info>
    <org_study_id>HS-10159-I-01</org_study_id>
    <nct_id>NCT02140606</nct_id>
  </id_info>
  <brief_title>Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)</brief_title>
  <official_title>An Open Phase I Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Cafusertib Hydrochloride in Combination With Subcutaneous Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability of cafusertib combination with low dose cytarabine&#xD;
      (LD-Ara-C) in Chinese patients with relapsed/refractory AML that are not eligible for&#xD;
      conventional or intensive treatment. The dose of cafusertib will be escalated to determine&#xD;
      the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cafusertib in&#xD;
      combination with LD-Ara-C in AML patients. At the same time, pharmacokinetic characteristics&#xD;
      and preliminary efficacy of cafusertib will be observed in AML patients. To determine the&#xD;
      recommended dosage regimen for phase II.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of cafusertib in combination with LDAraC based on the incidence of dose limiting toxicities</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (complete remission, CR; complete remission with incomplete blood count recovery, Cri; Partial remission (PR))</measure>
    <time_frame>minimum 4 weeks, maximum n.a.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events graded according to CTCAE (version 4.0)</measure>
    <time_frame>minimum 4 weeks, maximum n.a.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of cafusertib</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Cafusertib Hydrochloride + Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cafusertib Hydrochloride</intervention_name>
    <description>Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.</description>
    <arm_group_label>Cafusertib Hydrochloride + Cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent consistent with Chinese Good Clinical Practice.&#xD;
&#xD;
          -  Male or female patients of age &gt;/= 18 years at the time of informed consent.&#xD;
&#xD;
          -  Patients with relapsed/refractory AML ineligible for conventional or intensive&#xD;
             treatment.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status score 0 - 2 at screening.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Adequate hepatic, renal and metabolic function parameters: Serum total bilirubin ≤1.5&#xD;
             x upper limit of normal, aspartate transaminase (AST) , alanine transaminase (ALT)&#xD;
             ≤2.5 x upper limit of normal; Creatinine clearance rate ≥60ml/min, Serum creatinine&#xD;
             ≤1.0 x upper limit of normal; Relatively normal ECG(electrocardiogram), QTc&lt;450&#xD;
             ms(male) ,QTc&lt;470 ms(female); LVEF&gt;50%.&#xD;
&#xD;
          -  Patients who can comply with the trial and follow-up procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients had received cafusertib hydrochloride or other PLK inhibitors.&#xD;
&#xD;
          -  Patients with APL.&#xD;
&#xD;
          -  Patients with central nervous system leukemia.&#xD;
&#xD;
          -  Need to continue using cytokine therapy at screening.&#xD;
&#xD;
          -  Patients participated in other clinical trials within 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Patient with severe infection.&#xD;
&#xD;
          -  Patients with myocardial infarction had occurred within six months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Severe heart disease, including NYHA class II cardiac dysfunction and above.&#xD;
&#xD;
          -  Patients with HIV infection or acute and chronic viral hepatitis.&#xD;
&#xD;
          -  Severe gastrointestinal disorders (bleeding, infection, obstruction or greater than&#xD;
             grade 1 diarrhea).&#xD;
&#xD;
          -  A previous history of neurological or psychiatric disorders, including epilepsy or&#xD;
             dementia.&#xD;
&#xD;
          -  Concomitant medications with CYP3A4 inhibitors, inducers or substrates; Women pregnant&#xD;
             or breast feeding.&#xD;
&#xD;
          -  Subject is thought unfit for this study by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianxiang Wang</last_name>
    <phone>022 239099120</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Blood Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jianxiang Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>phase1</keyword>
  <keyword>MTD</keyword>
  <keyword>Cafusertib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

